| Age at disease onset (years) * | 34.2±13.6 | 37.2±11.7 | 36.9±11.9 | NS |
| Male sex | 17 (40%) | 167 (45%) | 184 (45%) | NS |
| Interval between symptom onset and diagnosis of BD (years) * | 8.4±10.7 | 8.6±10.0 | 8.6±10.1 | NS |
| Follow-up duration (years) * | 5.2±6.9 | 7.4±6.7 | 7.2±6.7 | 0.040 |
| HLA-B51 positivity | 6/18 (33%) | 118/230 (51%) | 124/248 (50%) | NS |
| Oral ulcers | 43 (100%) | 367 (100%) | 410 (100%) | NS |
| Genital ulcers | 33 (77%) | 266 (72%) | 299 (73%) | NS |
| Eye involvement | 15 (35%) | 251 (68%) | 266 (65%) | 0.000 |
| Skin involvement | 37 (86%) | 326 (88%) | 363 (88%) | NS |
| Arthritis | 32 (74%) | 166 (45%) | 198 (48%) | 0.000 |
| Epididymitis | 1/17 (6%) | 10/167 (6%) | 11/184 (6%) | NS |
| Central nervous system involvement | 2 (5%) | 52 (14%) | 54 (13%) | NS |
| Vascular involvement | 8 (19%) | 18 (5%) | 26 (6%) | 0.000 |
| Pathergy test positivity | 4/12 (33%) | 50/108 (46%) | 54/120 (45%) | NS |
| Complete type | 12 (28%) | 131 (36%) | 143 (35%) | NS |
| ISG criteria | 30 (70%) | 340 (92%) | 370 (90%) | 0.000 |